دورية أكاديمية
Transcriptomics-based characterization of the immuno-stromal microenvironment in pediatric low-grade glioma.
العنوان: | Transcriptomics-based characterization of the immuno-stromal microenvironment in pediatric low-grade glioma. |
---|---|
المؤلفون: | Körner M; Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Research Institute Children's Cancer Center Hamburg, Hamburg, Germany., Spohn M; Research Institute Children's Cancer Center Hamburg, Hamburg, Germany.; Bioinformatics Core, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Schüller U; Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Research Institute Children's Cancer Center Hamburg, Hamburg, Germany.; Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Bockmayr M; Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Research Institute Children's Cancer Center Hamburg, Hamburg, Germany.; bAIome - Center for Biomedical AI, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany. |
المصدر: | Oncoimmunology [Oncoimmunology] 2024 Aug 09; Vol. 13 (1), pp. 2386789. Date of Electronic Publication: 2024 Aug 09 (Print Publication: 2024). |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2015- : Philadelphia, PA : Taylor & Francis Original Publication: Austin, TX : Landes Bioscience |
مواضيع طبية MeSH: | Tumor Microenvironment*/immunology , Tumor Microenvironment*/genetics , Glioma*/genetics , Glioma*/immunology , Glioma*/pathology , Brain Neoplasms*/genetics , Brain Neoplasms*/pathology , Brain Neoplasms*/immunology, Humans ; Child ; Female ; Male ; Neoplasm Grading ; Gene Expression Profiling ; Transcriptome ; Child, Preschool ; Adolescent ; Stromal Cells/pathology ; Stromal Cells/metabolism ; Stromal Cells/immunology |
مستخلص: | Immunologic treatment options are uncommon in low-grade gliomas, although such therapies might be beneficial for inoperable and aggressive cases. Knowledge of the immune and stromal cells in low-grade gliomas is highly relevant for such approaches but still needs to be improved. Published gene-expression data from 400 low-grade gliomas and 193 high-grade gliomas were gathered to quantify 10 microenvironment cell populations with a deconvolution method designed explicitly for brain tumors. First, we investigated general differences in the microenvironment of low- and high-grade gliomas. Lower-grade and high-grade tumors cluster together, respectively, and show a general similarity within and distinct differences between these groups, the main difference being a higher infiltration of fibroblasts and T cells in high-grade gliomas. Among the analyzed entities, gangliogliomas and pleomorphic xanthoastrocytomas presented the highest overall immune cell infiltration. Further analyses of the low-grade gliomas presented three distinct microenvironmental signatures of immune cell infiltration, which can be divided into T-cell/dendritic/natural killer cell-, neutrophilic/B lineage/natural killer cell-, and monocytic/vascular/stromal-cell-dominated immune clusters. These clusters correlated with tumor location, age, and histological diagnosis but not with sex or progression-free survival. A survival analysis showed that the prognosis can be predicted from gene expression, clinical data, and a combination of both with a support vector machine and revealed the negative prognostic relevance of vascular markers. Overall, our work shows that low- and high-grade gliomas can be characterized and differentiated by their immune cell infiltration. Low-grade gliomas cluster into three distinct immunologic tumor microenvironments, which may be of further interest for upcoming immunotherapeutic research. Competing Interests: No potential conflict of interest was reported by the author(s). (© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.) |
References: | Neuro Oncol. 2010 Dec;12(12):1257-68. (PMID: 20861086) Oncoimmunology. 2021 Jun 17;10(1):1932365. (PMID: 34235002) Mol Ther Oncolytics. 2020 Dec 25;20:34-47. (PMID: 33575469) Cancer Cell. 2017 Mar 13;31(3):326-341. (PMID: 28292436) Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97. (PMID: 32368178) Cancer Res. 2005 Jan 1;65(1):76-84. (PMID: 15665281) PLoS Med. 2016 Dec 13;13(12):e1002194. (PMID: 27959923) Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):. (PMID: 28213438) Clin Cancer Res. 2016 Aug 15;22(16):4057-66. (PMID: 26994146) Acta Neuropathol. 2013 Aug;126(2):291-301. (PMID: 23660940) Neuro Oncol. 2013 Jul;15(7):865-79. (PMID: 23645533) Semin Cancer Biol. 2018 Oct;52(Pt 2):151-157. (PMID: 29990622) Nat Med. 2013 Nov;19(11):1423-37. (PMID: 24202395) Nat Genet. 2013 Aug;45(8):927-32. (PMID: 23817572) J Immunother Cancer. 2017 Feb 21;5:18. (PMID: 28239471) Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800) Cancer Res. 2009 Dec 1;69(23):9065-72. (PMID: 19920198) Front Immunol. 2020 Feb 13;11:205. (PMID: 32117316) Oncoimmunology. 2018 May 24;7(9):e1462430. (PMID: 30228931) Front Cell Dev Biol. 2021 Oct 29;9:721897. (PMID: 34778248) Nature. 2023 May;617(7962):807-817. (PMID: 37198490) J Immunol. 2013 Nov 1;191(9):4880-8. (PMID: 24078694) Cancer Immunol Res. 2019 Sep;7(9):1401-1411. (PMID: 31266783) Genome Biol. 2016 Oct 20;17(1):218. (PMID: 27765066) Cancer. 2009 Dec 15;115(24):5761-70. (PMID: 19813274) Commun Biol. 2023 Apr 11;6(1):394. (PMID: 37041233) Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517) Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):149-156. (PMID: 30684665) Cancer Cell. 2020 Apr 13;37(4):569-583.e5. (PMID: 32289278) Neuro Oncol. 2015 Nov;17(11):1486-96. (PMID: 25825052) Nat Commun. 2020 Aug 28;11(1):4324. (PMID: 32859926) Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076) Neuro Oncol. 2024 Mar 4;26(3):473-487. (PMID: 37870293) BMC Cancer. 2015 Oct 24;15:778. (PMID: 26497896) Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1060-1068. (PMID: 25035209) J Immunother Cancer. 2020 Aug;8(2):. (PMID: 32788236) J Neurosurg. 2011 Sep;115(3):505-11. (PMID: 21663411) Mol Oncol. 2020 Sep;14(9):2081-2095. (PMID: 32392361) Genome Med. 2023 Sep 7;15(1):67. (PMID: 37679810) Biosci Rep. 2021 Jan 29;41(1):. (PMID: 33345275) J Neurooncol. 2006 Jun;78(2):199-205. (PMID: 16739030) J Neuropathol Exp Neurol. 2017 Sep 1;76(9):779-788. (PMID: 28859336) Nature. 2022 Mar;603(7903):934-941. (PMID: 35130560) Cancer Res. 2007 Feb 1;67(3):890-900. (PMID: 17283119) |
فهرسة مساهمة: | Keywords: Astrocytoma; deconvolution; gene expression; low-grade glioma; tumor microenvironment |
تواريخ الأحداث: | Date Created: 20240813 Date Completed: 20240813 Latest Revision: 20240814 |
رمز التحديث: | 20240814 |
مُعرف محوري في PubMed: | PMC11318680 |
DOI: | 10.1080/2162402X.2024.2386789 |
PMID: | 39135890 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2162-402X |
---|---|
DOI: | 10.1080/2162402X.2024.2386789 |